Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dolutegravir and Simeprevir Drug Interaction Study
NCT02404805Phase 1Completed
- Sponsor
- University of Colorado Denver
- Start
- Feb 2016
- Primary completion
- Oct 2016
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of dolutegravir and simeprevir in human immunodeficiency virus infection (HIV) and hepatitis C (HCV), sponsored by University of Colorado Denver. Started Feb 2016; status: completed.
02
Drugs
dolutegravirsimeprevir
03
Conditions
human immunodeficiency virus infection (HIV)hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02404805.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02404805.